Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]
Proposed [GID-TA10654] Expected publication date: TBC
Search results
152 results
-
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
Proposed [GID-TA10714] Expected publication date: TBC
-
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
Amivantamab for non-small cell lung cancer [ID3836]
Proposed [GID-TA10729] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Proposed [GID-TA10598] Expected publication date: TBC
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
Proposed [GID-TA10691] Expected publication date: TBC
-
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Proposed [GID-TA10694] Expected publication date: TBC
-
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]
Proposed [GID-TA10698] Expected publication date: TBC
-
Etranacogene dezaparvovec for treating haemophilia B [ID3812]
Proposed [GID-TA10699] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Proposed [GID-TA10702] Expected publication date: TBC
-
Eptinezumab for preventing migraine [ID3803]
Proposed [GID-TA10677] Expected publication date: TBC
-
Gefapixant for treating refractory chronic cough [ID3789]
Proposed [GID-TA10678] Expected publication date: TBC
-
Remimazolam for general anaesthesia [ID3796]
Proposed [GID-TA10679] Expected publication date: TBC
-
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]
Proposed [GID-TA10680] Expected publication date: TBC
-
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Proposed [GID-TA10682] Expected publication date: TBC
-
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Proposed [GID-TA10684] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Proposed [GID-TA10683] Expected publication date: TBC
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]
Proposed [GID-TA10660] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 28 January 2021.
-
Anakinra for treating active Stills disease [ID1463]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 27 January 2021.
-
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Proposed [GID-TA10733] Expected publication date: TBC
-
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818
Proposed [GID-HST10040] Expected publication date: TBC
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 11 February 2021.
-
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]
Proposed [GID-HST10038] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Proposed [GID-TA10681] Expected publication date: TBC
-
Ibalizumabtreating for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Proposed [GID-TA10657] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Proposed [GID-TA10720] Expected publication date: TBC
-
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Proposed [GID-TA10605] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]
Proposed [GID-TA10781] Expected publication date: 22 September 2021
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 16 February 2021.
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 12 February 2021.
-
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Proposed [GID-TA10788] Expected publication date: TBC
-
Timrepigene emparvovec for treating choroideremia [ID3916]
Proposed [GID-TA10787] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
Proposed [GID-TA10786] Expected publication date: TBC
-
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]
Proposed [GID-TA10785] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]
Proposed [GID-TA10784] Expected publication date: TBC
-
Pegunigalsidase alfa for treating Fabry disease [ID3904]
Proposed [GID-TA10790] Expected publication date: TBC
-
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]
Proposed [GID-TA10789] Expected publication date: TBC
-
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Proposed [GID-TA10783] Expected publication date: TBC
-
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Proposed [GID-TA10791] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Proposed [GID-TA10795] Expected publication date: TBC
-
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]
Proposed [GID-TA10792] Expected publication date: TBC
-
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]
Proposed [GID-TA10796] Expected publication date: TBC
-
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]
Proposed [GID-TA10793] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Proposed [GID-TA10797] Expected publication date: TBC
-
Brolucizumab for treating diabetic macular oedema [ID3902]
Proposed [GID-TA10794] Expected publication date: TBC
-
Faricimab for treating diabetic macular oedema [ID3899]
Proposed [GID-TA10798] Expected publication date: TBC
-
Faricimab for treating wet age-related macular degeneration [ID3898 ]
Proposed [GID-TA10799] Expected publication date: TBC